The boy, o years old, became acutely ill. The beginning is with an increase in body temperature to 380C, the appearance of swelling in the parotid gland on the right, pain when chewing. After 2 days, there was swelling and soreness in the area of the left parotid gland. There is pain when pressing on the tragus. mastoid process and in the area of the retromandibulur fossa. Dynamics of the disease: on the 5th day of the disease, he began to complain of headache, again an increase in body temperature and vomiting. Objectively. The condition is of moderate severity. Body temperature is 38 C. Rigidity of the occipital muscles by 2.5 transverse fingers, positive symptoms of Upper Brudzinsky, Kerniga on both sides. The heart tones are clear, rhythmic. Heart rate is 102 per minute. There is vesicular breathing in the lungs, there are no wheezing. The abdomen is soft, painless, the liver and spleen are not enlarged. The chair is decorated. Urintion is not disturbed. General blood test: NI-120 g/l, Er-4.5×1012/1, CP-0.89, Lake-4, 0x109/l; p/1-3%, s/1-37%, 1-60%, ESR-7 spinal puncture: cerebrospinal fluid-flows out in frequent drops, transparent, cytosis-385 cells/ml, of which: lymphocytes-353/ml, neutrophils-52/ml./ 1.Permilanry diagnosis according to form and severcity 2.differnatial diagnosis 3.diagnosis ,lab test 4.treatment 5.prevenation
Checking Date & Time
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information to provide a thorough clinical answer. Let me compile everything.
Clinical Analysis: Mumps (Epidemic Parotitis) Complicated by Serous (Aseptic) Meningitis
1. Preliminary Diagnosis — Form and Severity
Primary Diagnosis:
Epidemic Parotitis (Mumps) — severe form, complicated by serous (aseptic) meningitis
Justification:
| Clinical Feature | Significance |
|---|---|
| Acute onset with fever 38°C | Systemic viral illness |
| Sequential bilateral parotid swelling (right → left, 2 days apart) | Classic for mumps |
| Pain on chewing, tenderness at tragus, mastoid, retromandibular fossa | Parotid gland involvement |
| Day 5: fever recurrence + headache + vomiting | CNS complication onset |
| Neck rigidity (2.5 finger-breadths), Kernig's + Brudzinski's signs (bilateral) | Meningeal syndrome |
| CSF: transparent, flows in frequent drops (elevated pressure), cytosis 385 cells/µL with lymphocytic predominance (353/µL lymphocytes) | Serous (viral) meningitis pattern |
| CBC: Leukocytes 4.0×10⁹/L with lymphocytosis 60%, ESR 7 mm/hr | Viral (not bacterial) pattern |
Severity: Moderate-to-severe (uncomplicated parotitis = mild; CNS involvement elevates to moderate/severe requiring hospitalization).
Mumps virus is highly neurotropic — subclinical CNS involvement (CSF pleocytosis) occurs in up to 55% of cases; symptomatic aseptic meningitis occurs in up to 10% of unvaccinated patients. — Harrison's Principles of Internal Medicine, 22e
2. Differential Diagnosis
A. Differential for Parotid Swelling
| Condition | Features that ARGUE AGAINST it here |
|---|---|
| Suppurative (bacterial) parotitis | Rapid onset, pus from Stensen's duct, marked erythema/warmth, high neutrophilic leukocytosis — none present |
| Buccal cellulitis | Erythematous, tender facial swelling; requires non-immunized + H. influenzae |
| Masseter space abscess | Trismus, dental history, unilateral |
| Sjögren's syndrome / Sarcoidosis | Chronic, gradual; no fever, no epidemic context |
| Salivary duct stone (sialolithiasis) | No infection signs, swelling worse with eating |
| Parotid neoplasm | Painless, gradual, no fever |
Key distinguishing feature of mumps: gradual onset, tense non-erythematous gland, no pus from Stensen's duct, bilateral sequential involvement, absent warmth.
B. Differential for Meningeal Syndrome
| Condition | CSF Pattern | Why excluded here |
|---|---|---|
| Bacterial meningitis (e.g., pneumococcal, meningococcal) | Turbid/purulent; neutrophilic pleocytosis; low glucose; elevated protein | CSF here is transparent with lymphocytic predominance; glucose likely normal; ESR low; WBC not elevated |
| Tuberculous meningitis | Lymphocytic, very elevated protein, low glucose; subacute course | No TB history; acute course; parotitis context |
| Enteroviral meningitis | Clinically indistinguishable from mumps meningitis | No parotitis; season/epidemiology |
| Mumps meningitis ✓ | Transparent CSF, lymphocytic pleocytosis 10–2000/µL, normal glucose, mild protein elevation | Matches perfectly |
| Herpes simplex encephalitis | Hemorrhagic CSF, focal neurological signs, temporal lobe changes | No focal signs; no altered consciousness |
The transparent CSF + lymphocytic predominance + concurrent parotitis = mumps meningitis until proven otherwise.
3. Diagnosis & Laboratory Tests
Confirmed Diagnosis:
Epidemic parotitis (mumps) complicated by serous meningitis — moderate-severe form
Diagnostic Workup:
Already performed:
- ✅ CBC — leukopenia with lymphocytosis (viral pattern)
- ✅ Lumbar puncture with CSF analysis — confirms serous meningitis
Additional tests indicated:
| Test | Rationale |
|---|---|
| Serum amylase / lipase | Rule out pancreatitis (amylase elevated in both parotitis AND pancreatitis; lipase is specific for pancreas) |
| Mumps RT-PCR (buccal swab, urine, CSF) | Gold standard — preferred for sensitivity & specificity; collect buccal swab after parotid massage for 30 sec; best within 5 days of symptom onset |
| Mumps serology (IgM/IgG) | IgM positive in acute infection; useful if virologic testing negative, especially in vaccinated patients |
| CSF glucose & protein | Serous meningitis: glucose normal or mildly reduced; protein mildly elevated |
| CSF Gram stain + bacterial culture | Rule out bacterial co-infection |
| Blood culture | Standard for febrile CNS presentation |
| Serum electrolytes, urea, creatinine | Baseline; renal involvement rare but possible |
| ECG | Mumps myocarditis/ECG changes in up to 15% |
| Vaccination history | Critical epidemiological data |
Buccal swabs provide the best specimens for virus detection. The parotid gland should be massaged for 30 s prior to collection. As maximal viral shedding occurs within 5 days after symptom onset, specimens ideally should be collected as early as possible. — Harrison's Principles of Internal Medicine, 22e
CSF Interpretation Summary:
| Parameter | This Case | Serous Meningitis (expected) | Bacterial Meningitis (contrast) |
|---|---|---|---|
| Appearance | Transparent | Clear/transparent | Turbid/cloudy |
| Pressure | Elevated (frequent drops) | Mildly elevated | Markedly elevated |
| Cytosis | 385 cells/µL | 10–2000/µL | >1000/µL (neutrophils) |
| Lymphocytes | 353/µL (91%) | Predominant | Minority |
| Glucose | (not reported) | Normal or slightly ↓ | Markedly ↓ |
| Protein | (not reported) | Mildly ↑ | Markedly ↑ |
4. Treatment
A. General Measures
- Hospital admission is mandatory — CNS involvement with meningeal signs
- Bed rest in a darkened, quiet room (meningeal irritation)
- Adequate fluid intake / IV fluids if oral intake is poor
- Parotid area: warm or cold compresses for comfort
B. Symptomatic/Supportive Treatment
| Drug | Indication | Dose |
|---|---|---|
| Ibuprofen / Paracetamol | Fever, headache, parotid pain | Age-appropriate dosing |
| Analgesics (paracetamol 15 mg/kg/dose q6h) | Pain management | Standard pediatric dosing |
| IV dexamethasone (optional, adjunctive) | Reduction of meningeal inflammation in severe cases | 0.15 mg/kg q6h × 4 days (evidence mainly for bacterial; used judiciously in severe viral cases with high ICP) |
C. Antiviral Therapy
- No specific antiviral is available or proven effective for mumps. Treatment is entirely supportive.
- Mumps immune globulin is not recommended for treatment or post-exposure prophylaxis.
D. Monitoring
- Neurological status (GCS, meningeal signs)
- Vital signs, fluid balance
- Repeat CSF if no improvement at 48–72 hours
- Audiology assessment — sensorineural hearing loss occurs in up to 4% (sudden onset, usually unilateral)
- Monitor for orchitis if male/postpubertal
E. Isolation
- The child is infectious from 2 days before to 9 days after parotid swelling onset
- Respiratory (droplet) isolation in hospital
- Exclude from school/daycare for 9 days after onset of parotid swelling
Immunocompetent patients with isolated viral parotitis or orchitis can be managed as outpatients. Admit patients with systemic complications. — Tintinalli's Emergency Medicine
5. Prevention
Active Immunization — MMR Vaccine
| Parameter | Detail |
|---|---|
| Vaccine type | Live attenuated virus (Jeryl Lynn or RIT 4385 strains in most countries) |
| Standard schedule | Dose 1: 12–15 months of age; Dose 2: 4–6 years of age |
| Effectiveness | 1 dose: ~72%; 2 doses: ~86% against symptomatic mumps; measles component 97% effective |
| Vaccine formulations | MMR (measles-mumps-rubella) or MMRV (+ varicella, ages 12 months–12 years) |
| Outbreak management | Third dose recommended for at-risk groups during outbreaks |
| Contraindications | Immunocompromised individuals, pregnancy, severe allergy to vaccine components |
Non-Vaccine Measures
- Isolation of confirmed/suspected cases (9 days from parotid swelling onset)
- Droplet precautions in healthcare settings (surgical mask, single room)
- Hand hygiene, respiratory etiquette
- Contact tracing and monitoring of exposed unvaccinated individuals
- Report to public health authorities (notifiable disease in most countries)
Mumps vaccines are generally very safe. The Jeryl Lynn and RIT 4385 strains are the only strains used in the United States and carry no increased risk of vaccine-associated aseptic meningitis, unlike older Urabe and Leningrad-Zagreb strains. — Harrison's Principles of Internal Medicine, 22e
Summary Table
| Item | Answer |
|---|---|
| Preliminary diagnosis | Epidemic parotitis (mumps) with serous meningitis — moderate-severe form |
| Causative agent | Mumps paramyxovirus |
| Key DDx for parotitis | Suppurative parotitis, sialolithiasis, Sjögren's |
| Key DDx for meningitis | Bacterial meningitis, enteroviral meningitis, TB meningitis |
| Confirmatory test | Mumps RT-PCR (buccal swab + urine + CSF) |
| Treatment | Supportive (antipyretics, analgesia, IV fluids, bed rest); no antiviral; admit |
| Isolation | Droplet precautions; exclude from school ×9 days |
| Prevention | MMR vaccine ×2 doses (12–15 months + 4–6 years) |
This is a shared conversation. Sign in to Orris to start your own chat.